Zivo Bioscience (ZIVO) Stock Price

Zivo Bioscience Price

NYSE·CLOSED
4.97
​
Market closed

Revenue at Zivo Bioscience has contracted by 4.7% per year over the past 19 years to 119,025.00 USD. For Zivo Bioscience, the net margin of -8,311.1% is up versus -48,278.9% a few years ago. The consensus 12-month price target for Zivo Bioscience is 12.24 USD, about 146.3% above where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.

Zivo Bioscience stock price

Access this data via the Eulerpool API

Zivo Bioscience business model & stock analysis

Zivo Bioscience, Inc. engages in the study, development, and commercialization of natural nutritional compounds and bioactive molecules from its proprietary algal strains. The company is headquartered in Keego Harbor, Michigan and currently employs 8 full-time employees. The company went IPO on 2000-10-06. The firm is engaged in the study, development and commercialization of naturally derived compounds and bioactive molecules created by algal and bacterial hosts. The firm focuses on research and identification of its bioactive ingredients. The company focuses to sell natural bioactive ingredients derived from its algae cultures to animal, human and dietary supplement and medical food manufacturers. The company is also engaged in development of biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation. The company focuses on developing, manufacturing, marketing and selling tests that allow users to optimize personal health and identify future health risks. The firm manufactures algal products and derivatives, and has various product platforms.

Frequently asked questions about Zivo Bioscience

Analysts currently set an average price target of 12.24 USD for the Zivo Bioscience stock (median: 12.24 USD), implying +146.3 % versus the latest price. The consensus is based on 7 analyst ratings.

6 analysts currently rate the Zivo Bioscience stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Zivo Bioscience to generate revenue of 1.19 M USD and earnings per share of -1.08 USD.

Converted at the current exchange rate, the Zivo Bioscience share trades at 4.44 EUR (4.97 USD).

The expected revenue of Zivo Bioscience is 1.19 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Zivo Bioscience is -4.20 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Zivo Bioscience is currently -4.60. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Zivo Bioscience stock.

The price-to-sales ratio (P/S) of Zivo Bioscience is currently 16.28. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Zivo Bioscience stock.

The Eulerpool Quality Score for Zivo Bioscience is 4/10.

The ISIN of Zivo Bioscience is US98978N3098. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Zivo Bioscience is ZIVO. The ticker symbol is used to trade Zivo Bioscience shares on the stock exchange.

Fair ValueTerminal
4.97 USD
Over-/UndervaluationTerminal
Fairly valued
Industry
Personal Products
Number of shares
Employees
Revenue per Employee
14,878.13 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Oct 6, 2000
ISIN
US98978N3098
Cusip
98978N101
Sedol
BSL7HN7
Market capitalization
19.33 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-4.60
P/Ee 2027
-5.51
P/Se
16.28
EV/EBIT
—
P/B Ratio
3.20
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
318.00 %
Last updated Oct 12, 2026, 3:43 PM